Sentences with phrase «cell replacement therapies as»

Not exact matches

HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.

Regardless of the targeted organ for cell replacement or regeneration, the shared challenges in cell therapies for diabetes such as transplant procedure and immune rejection will be well - served by the collective expertise within CCTD.

Cell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etCell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etc.).

ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.

Basically what was happening when you use a hematopoietic stem cell to correct an inherited metabolic disease is that through engraftment of that cell you are allowing that cell to become the replacement source for the missing enzyme or other factor - almost like a cellular form of gene therapy or, as I call it, «poor man's gene therapy».

In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.

San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follcell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follCell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:

With the STEP ONE trial underway, and the addition of W. L. Gore & Associates as collaborators to optimize the Encaptra ® cell delivery system, ViaCyte felt that the PEC - Direct approach might be the most rapid way to get the invaluable PEC - 01 cell replacement therapy to those who need it most.

The PEC - Encap (also known as VC - 01) product candidate is designed to deliver stem cell - derived islet replacement therapies to patients with type 1 diabetes as well as patients with type 2 disease that require insulin.

A number of treatments exist, including enzyme replacement therapy and hematopoietic stem cell transplantation, but efficacy depends upon diagnosing the disease and its specific form as early as possible.

San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

«Dr. Ding's latest research offers new hope for the process of developing medications for these diseases, as well as for the possibility of cell - replacement therapy to reduce the trauma of millions of people affected by these devastating and irreversible conditions.»

«In particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell - derived cell replacement therapy.

As the first company to advance a cell replacement therapy for type 1 diabetes into the clinic, ViaCyte is committed to developing a functional cure for all type 1 diabetes patients.

In BHRT (Bioidentical Hormone Replacement Therapy), natural progesterone is seen as a highly effective treatment as it can counteract the effects of estrogen, which naturally stimulates cell growth in tissues containing estrogen receptors and contributes to symptoms of endometriosis.

Stem cell therapy offers the possibility of using these stem cells to grow into replacements for injured or diseased tissues such as bone, cartilage, muscle, nerves, and so on.